During the past decade, Haematologische / Onkologische Schwerpunktpraxis conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Haematologische / Onkologische Schwerpunktpraxis" #1 sponsor was "German CLL Study Group" with 1 trials, followed by "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials sponsored, "Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH" with 1 trials sponsored, "III. Medizinische Klinik Mannheim" with 1 trials sponsored and "Universität des Saarlandes" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Haematologische / Onkologische Schwerpunktpraxis" #1 collaborator was "Crolll Gmbh" with 1 trials as a collaborator, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials as a collaborator and "Spectrum Pharmaceuticals, Inc" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Haematologische / Onkologische Schwerpunktpraxis" are "CD20+ Aggressive B-Cell Lymphoma" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Chronic Myelogenous Leukemia (CML)" (1 trials), "Leukemia" (1 trials) and "Lymphoma" (1 trials). Many other conditions were trialed in "Haematologische / Onkologische Schwerpunktpraxis" in a lesser frequency.

Most popular intervention types in "Haematologische / Onkologische Schwerpunktpraxis" are "Drug" (4 trials), "Biological" (2 trials), "Other" (2 trials), "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (2 trials), "radiation therapy" (2 trials), "Conventional Vincristine" (1 trials), "Liposomal Vincristine" (1 trials) and "Ricover-scheme rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Haematologische / Onkologische Schwerpunktpraxis" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Haematologische / Onkologische Schwerpunktpraxis". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Haematologische / Onkologische Schwerpunktpraxis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Haematologische / Onkologische Schwerpunktpraxis, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".